(NASDAQ: INVA) Innoviva's forecast annual revenue growth rate of 8.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.15%.
Innoviva's revenue in 2025 is $370,229,000.On average, 7 Wall Street analysts forecast INVA's revenue for 2025 to be $24,409,299,142, with the lowest INVA revenue forecast at $23,206,227,985, and the highest INVA revenue forecast at $25,489,479,322. On average, 7 Wall Street analysts forecast INVA's revenue for 2026 to be $27,240,833,302, with the lowest INVA revenue forecast at $24,166,668,239, and the highest INVA revenue forecast at $30,002,414,135.
In 2027, INVA is forecast to generate $29,970,273,418 in revenue, with the lowest revenue forecast at $25,818,449,016 and the highest revenue forecast at $34,800,203,931.